Abstract: The present invention relates to a preparation for injection including an isoxazoline derivative useful as a caspase inhibitor or a pharmaceutically acceptable salt thereof as an active pharmaceutical ingredient (API). The preparation for injection according to the present invention includes the first solution composed of a high-dose API and the second solution including a reconstitution solution, so that it can be prepared by mixing the first formulation and the second formulation immediately before administration to a patient, and contains the Active-API stably. Therefore, there is an advantage that effective drug efficacy can be expected when administered to a patient.

Abstract: A battery module and an energy storage device including a battery rack including a plurality of battery modules, and a rack fuse cutting off a circuit when an overcurrent occurs in the battery rack, each of the plurality of battery modules includes a battery cell and a module fuse that cuts off a circuit when an overcurrent occurs in the battery module, the module fuse has a voltage specification capable of corresponding to an output voltage of the battery rack, and has a short circuit specification lower than a short circuit specification of the rack fuse.

Abstract: The present invention relates to an amorphous compound represented by formula 1, a method for preparing the same, and a pharmaceutical composition comprising the same. The amorphous compound represented by formula 1 of the present invention may be characterized by XRD patterns, DSC profiles, and/or TGA profiles.

Abstract: The present invention relates to a pharmaceutical formulation for injection comprising an isoxazoline derivative useful as a caspase inhibitor or a pharmaceutically acceptable salt thereof as an active pharmaceutical ingredient (API). The pharmaceutical formulation for injection according to the present invention includes the first formulation composed of a high-dose API and the second formulation including a reconstitution solution, so that it can be prepared by mixing the first formulation and the second formulation immediately before administration to a patient, and contains the Active-API stably. Therefore, there is an advantage that effective drug efficacy can be expected when administered to a patient.

Abstract: The present disclosure relates to an organoid selection device and method, and, particularly, can provide an organoid selection device and method, which enable a mature organoid to be selected from an image by using an artificial intelligence model. Particularly, provided is a device, which constructs and verifies an artificial intelligence model so as to use only image information about an organoid, and thus can more accurately select a mature organoid exhibiting uniform efficacy.

Abstract: The present invention relates to an injectable formulation containing, as an active pharmaceutical ingredient (API), an isoxazoline derivative or pharmaceutically acceptable salt thereof useful as a caspase inhibitor. The injectable formulation according to the present invention includes a first agent composed of a high dose of the API, and a second agent that is a solvent capable of dissolving the first agent, and may be prepared by mixing the first agent and the second agent immediately before administration. The injectable formulation stably contains the active API and thus has the advantage that effective drug efficacy can be expected when administered to a patient.

Abstract: The present invention relates to an injectable pharmaceutical composition containing a prodrug of caspase inhibitors, and a preparation method therefor. More specifically, the present invention relates to an injectable pharmaceutical composition, and a preparation method therefor, the composition comprising, as an active ingredient, (2S,3S)-2-(fluoromethyl)-3-((R)-5-isopropyl-3-(isoquinolin-1-yl)-4,5-dihydroisoxazole-5-carboxamido)-5-oxotetrahydrofuran-2-yl acetate, which is a prodrug of caspase inhibitors, or a pharmaceutically acceptable salt or isomer thereof, and comprising, as a biocompatible polymer, microspheres containing poly(lactide-co-glycolide).

Abstract: The present invention relates to a tubular scaffold and a method of manufacturing the same. The tubular scaffold has physical properties matching the characteristics of a tubular organ that bends or rotates when a double layer is formed by electrospinning nanofibers, and not only has excellent cell adhesion ability but may also maintain cell functions. Also, since such effects have been proven in an animal model, the tubular scaffold may be mass-produced and used as a highly functional tubular organ having various sizes and lengths.

Abstract: The present invention relates to a method of manufacturing an alveolar organoid using alveolar cell-derived induced pluripotent stem cells. The alveolar organoid manufactured according to the present invention is differentiated from the human alveolar cell-derived induced pluripotent stem cells, and thus induced pluripotent stem cells may efficiently differentiate into alveolar organoids due to the epigenetic memory of alveolar cells. Therefore, the alveolar organoids are expected to be effectively used for research on the pathological process of respiratory diseases, screening for finding therapeutic drugs, and the like.

Abstract: The present invention relates to a method for manufacturing mycelium mat into leather by using pH-controlled tannic acid. The method comprises the following steps: (1) inactivating the mycelium mat; (2) infiltrating the mycelium mat with a polysaccharide solution; (3) treating the polysaccharide-infused mycelium mat with a tannic acid solution; and (4) introducing a buffering agent to the tannic acid-treated mycelium mat. This innovative approach enhances the mechanical properties of the resulting leather, offering an environmentally friendly alternative to conventional leather materials.

Abstract: An embodiment barricade for suppressing a behavior of a spare tire includes a support portion configured to be mounted on a spare tire well panel and a protruding portion extending from the support portion and protruding to a spare tire side. In an embodiment, the protruding portion is spaced apart from the spare tire well panel.

Abstract: A lower side structure of a vehicle includes a side sill outer having a convex cross-section shape that is convexly curved toward an outside of the vehicle, a center floor main panel which has both side ends bonded to an upper end of the side sill outer and forms a floor of a vehicle, and a lower member having both ends bonded to a lower end portion of the side sill outer and assembled to a lower portion of the center floor main panel. In particular, a closed cross-section is formed between the side sill outer, the center floor main panel, and the lower member.

Abstract: Discussed is a battery swapping station, and a control method and a battery swapping system. The battery swapping station can include first to mth charging slots capable of storing and withdrawing a battery pack, respectively, an information input/output device configured to receive a battery replacement request from a user, and a controller configured to check battery storage information of the first to mth charging slots. The controller is configured to determine whether a battery withdrawal condition is satisfied in response to the battery replacement request, and switch a specific charging slot in which a fully charged battery pack is stored among the first to mth charging slots from a locked mode to an unlocked mode in response to the battery withdrawal condition being satisfied.

Abstract: The present invention relates to a method of developing a tissue-specific vascular endothelial cell line based on iPSCs derived from human tissue-specific cells. When an organoid is manufactured using the cell line based on the iPSCs derived from human tissue-specific cells, the organoid manufacturing period may be significantly shortened, thereby solving the problem of sustainability, which is a major drawback known in the related art, and may be stored conveniently, and thus may be easily used during each experiment, thereby greatly increasing efficiency. Also, the organoid manufactured from the cell line of the present invention may be usefully used in the manufacture of blood vessel organoids in that the organoid is not only tissue-specific but also exhibits an excellent level of morphological and functional maturity.

Abstract: A display device includes: a display panel including a first area and a second area extending from the first area in a first direction, a first support plate disposed on a bottom of the display panel in the first area, a second support plate disposed on a bottom of the display panel in the second area, and a plurality of holes formed in the second support plate and extending substantially perpendicular to the first direction.

Abstract: Disclosed is a method of producing vascularized respiratory (airway and alveolar) organoids using blood vessel organoids. More particularly, vascularized respiratory (airway and alveolar) organoids with a vascular network are produced by fusing respiratory (airway and alveolar) organoids with blood vessel organoids to induce vascularization. The vascularized respiratory (airway and alveolar) organoids can have functions very similar to the human respiratory whole region, so they are expected to be transplanted into humans to treat respiratory related diseases or be used as an in vitro respiratory whole region model.

Abstract: The present disclosure relates to the detection of beta amyloid protein as an Alzheimer's disease-causing factor in the palatine tonsil and a use thereof and, more specifically, to the diagnosis of Alzheimer's disease by identifying the expression of beta amyloid and/or Staphylococcus aureus in a tonsillar sample. The present disclosure can diagnose Alzheimer's disease through the expression of beta amyloid and/or Staphylococcus aureus in a palatine tonsil tissue and, furthermore, can be very advantageously used for revealing the pathogenesis of Alzheimer's disease and for treating Alzheimer's disease.

Abstract: The present invention relates to a method of producing an alveolar organoid by a dropping suspension culture technique using decellularized extracellular matrix (dECM) hydrogel, and according to the present invention, when an organoid is produced by a dropping suspension culture method using dECM, as in a living organism, an organoid in which cells and dECM are fused may be formed. Moreover, since dECM is what remains after all cells have been removed from tissue and thus is easily applied clinically, the produced organoid is expected to be useful for disease modeling, drug screening, regenerative medicine, etc.

Abstract: The present invention relates to a co-crystal of a compound represented by chemical formula 1 and vanillin, a method for preparing same, and a pharmaceutical composition comprising same. The co-crystal of the compound represented by chemical formula 1 and vanillin of the present invention has excellent chemical and physical stability and is characterized by the XRD pattern, DSC profile, and/or TGA profile.

Abstract: The present invention relates to a pharmaceutical composition comprising nasal inferior turbinate-derived mesenchymal stem cells as an active ingredient, the composition being administered by intranasal or intramaxillary administration by means of olfactory mucosa subepithelial injection, and the like, in order to bypass the blood-brain barrier through a peri-olfactory pathway.